Published in Eur Radiol on January 31, 2007
Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging (2010) 1.11
How reliable is current imaging in restaging rectal cancer after neoadjuvant therapy? World J Gastroenterol (2013) 0.95
Accuracy of transrectal ultrasound after preoperative radiochemotherapy compared to computed tomography and magnetic resonance in locally advanced rectal cancer. Int J Colorectal Dis (2012) 0.86
Is there a benefit in using magnetic resonance imaging in the prediction of preoperative neoadjuvant therapy response in locally advanced rectal cancer? Int J Colorectal Dis (2013) 0.85
Stage and size using magnetic resonance imaging and endosonography in neoadjuvantly-treated rectal cancer. World J Gastroenterol (2013) 0.84
MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary Report. Biomed Res Int (2015) 0.80
Imaging Advances in Colorectal Cancer. Curr Colorectal Cancer Rep (2016) 0.75
Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit. Am J Surg Pathol (2002) 3.09
Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg (2002) 2.89
Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet (2001) 2.64
Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg (2003) 2.40
Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet (2002) 2.38
Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology (1999) 1.82
Relationship between pathologic T-stage and nodal metastasis after preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg Oncol (2005) 1.79
Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. Br J Surg (2001) 1.59
Radiological findings do not support lateral residual tumour as a major cause of local recurrence of rectal cancer. Br J Surg (2006) 1.54
Diffusion-weighted magnetic resonance imaging for monitoring diffusion changes in rectal carcinoma during combined, preoperative chemoradiation: preliminary results of a prospective study. Eur J Radiol (2003) 1.52
Comparison of CT, MRI and FDG-PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol (2005) 1.49
Rectal cancer: review with emphasis on MR imaging. Radiology (2004) 1.47
High-resolution MRI of the anatomy important in total mesorectal excision of the rectum. AJR Am J Roentgenol (2004) 1.42
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum (2003) 1.25
Rectal tumour staging: MR imaging using pelvic phased-array and endorectal coils vs endoscopic ultrasonography. Eur Radiol (2000) 1.17
Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol (2005) 1.13
How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum (2005) 1.08
Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 1.07
Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys (2005) 0.96
Response to neoadjuvant therapy for rectal cancer: influence on long-term results. Colorectal Dis (2005) 0.94
Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging. Eur Radiol (2006) 0.93
Preoperative staging of colorectal cancer--computed tomography and magnetic resonance imaging. Scand J Surg (2003) 0.89
The mesorectum: morphometric assessment with magnetic resonance imaging. Eur Radiol (2005) 0.89
Rectal tumours--MR imaging with endorectal and/or phased-array coils, and histopathological staging on giant sections. A comparative study. Acta Radiol (1997) 0.88
Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer. Br J Surg (2003) 0.86
Whole-body imaging with MRI or PET/CT: the future for single-modality imaging in oncology? JAMA (2003) 0.84
Retrospective measurement of different size parameters of non-radiated rectal cancer on MR images and pathology slides and their comparison. Eur Radiol (2003) 0.82
Restaging of locally advanced carcinoma of the rectum with MR imaging after preoperative radio-chemotherapy plus regional hyperthermia. Strahlenther Onkol (2002) 0.79
Preoperative chemoradiotherapy in patients with locally advanced rectal cancer. Hepatogastroenterology (2005) 0.75
Dynamics of fat cell turnover in humans. Nature (2008) 9.80
Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol (2011) 5.75
Towards evidence-based guidelines for radiotherapy infrastructure and staffing needs in Europe: the ESTRO QUARTS project. Radiother Oncol (2005) 4.76
Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer (2009) 4.50
The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg (2007) 4.22
Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA (2003) 4.01
Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol (2012) 3.95
Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer (2006) 3.38
Ultraviolet radiation exposure and risk of malignant lymphomas. J Natl Cancer Inst (2005) 3.19
Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst (2005) 3.07
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol (2013) 2.94
Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol (2005) 2.91
Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol (2008) 2.68
Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol (2002) 2.63
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol (2008) 2.46
Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst (2002) 2.44
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg (2012) 2.43
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol (2002) 2.28
Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol (2007) 2.27
Evidence-based medicine: the time has come to set standards for staging. J Pathol (2010) 2.26
Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst (2006) 2.23
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol (2014) 2.17
Short-course preoperative radiotherapy with delayed surgery in rectal cancer - a retrospective study. Radiother Oncol (2008) 2.15
Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics (2008) 2.08
Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg (2002) 2.04
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol (2012) 2.02
Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups. J Natl Cancer Inst (2012) 1.99
A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-alpha)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes (2005) 1.94
A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab (2005) 1.87
Atopy and risk of non-Hodgkin lymphoma. J Natl Cancer Inst (2007) 1.87
Increasing incidence of paediatric inflammatory bowel disease in northern Stockholm County, 2002-2007. J Pediatr Gastroenterol Nutr (2013) 1.87
Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet (2013) 1.85
The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer (2010) 1.69
Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell (2009) 1.68
Reliability of self-reported family history of cancer in a large case-control study of lymphoma. J Natl Cancer Inst (2006) 1.68
Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer (2002) 1.66
Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature. Acta Oncol (2014) 1.64
Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol (2007) 1.60
GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. PLoS Genet (2011) 1.58
Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer (2007) 1.58
Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol (2005) 1.57
Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp Cell Res (2005) 1.57
Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol (2011) 1.55
Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol (2009) 1.55
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. J Natl Cancer Inst (2013) 1.54
Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients. Cancer (2009) 1.52
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol (2008) 1.46
Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res (2007) 1.45
Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol (2005) 1.45
Clinical benefit response in pancreatic cancer trials revisited. Oncol Res Treat (2014) 1.43
Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res (2009) 1.43
Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial. J Comput Assist Tomogr (2006) 1.43
Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int J Cancer (2004) 1.40
[Unexpected findings--sunlight can protect against cancer]. Lakartidningen (2005) 1.38
Rectal cancer irradiation. Long course, short course or something else? Acta Oncol (2006) 1.38
Long-term sequelae after cancer therapy--a necessary consequence of success? Acta Oncol (2004) 1.38
Magnetic resonance imaging for the clinical management of rectal cancer patients: recommendations from the 2012 European Society of Gastrointestinal and Abdominal Radiology (ESGAR) consensus meeting. Eur Radiol (2013) 1.37
Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol (2013) 1.34
Fecal calprotectin: a quantitative marker of colonic inflammation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2007) 1.30
NF-kappaB is important for TNF-alpha-induced lipolysis in human adipocytes. J Lipid Res (2007) 1.30
Dietary factors and risk of non-hodgkin lymphoma in men and women. Cancer Epidemiol Biomarkers Prev (2005) 1.29
Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am J Physiol Endocrinol Metab (2007) 1.29
Family history of hematopoietic malignancy and risk of lymphoma. J Natl Cancer Inst (2005) 1.29
SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am J Surg Pathol (2011) 1.27
Hepatitis C infection and risk of malignant lymphoma. Int J Cancer (2008) 1.27
HLA-A alleles and infectious mononucleosis suggest a critical role for cytotoxic T-cell response in EBV-related Hodgkin lymphoma. Proc Natl Acad Sci U S A (2010) 1.27
Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol (2011) 1.25
Interobserver and intraobserver variability in the response evaluation of cancer therapy according to RECIST and WHO-criteria. Acta Oncol (2010) 1.23
Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol (2002) 1.23
KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice. BMC Cancer (2010) 1.22
A systematic approach to the interpretation of preoperative staging MRI for rectal cancer. AJR Am J Roentgenol (2008) 1.22
Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer (2003) 1.17
Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun (2004) 1.16
Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer (2010) 1.16
Proton therapy of cancer: potential clinical advantages and cost-effectiveness. Acta Oncol (2005) 1.13
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol (2005) 1.13
Assessment of hepatic extraction fraction and input relative blood flow using dynamic hepatocyte-specific contrast-enhanced MRI. J Magn Reson Imaging (2009) 1.12
Magnetic resonance imaging (MRI) in rectal cancer: a comprehensive review. Insights Imaging (2010) 1.11
Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer (2005) 1.10
Breast cancer risk following radiotherapy for Hodgkin lymphoma: modification by other risk factors. Blood (2005) 1.09
Cancer survival in Sweden 1960-1998--developments across four decades. Acta Oncol (2003) 1.07
Late adverse effects of radiation therapy for rectal cancer - a systematic overview. Acta Oncol (2007) 1.07
Nutrient intake and risk of non-Hodgkin's lymphoma. Am J Epidemiol (2006) 1.06
Loco-regional recurrence from colon cancer: a population-based study. Ann Surg Oncol (2006) 1.06
Cellular studies of binding, internalization and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol (2007) 1.06
Epidermoid anal cancer: a review of a population-based series of 308 consecutive patients treated according to prospective protocols. Int J Radiat Oncol Biol Phys (2005) 1.04
Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev (2006) 1.03
Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer (2011) 1.01
The correlation between a family history of colorectal cancer and survival of patients with colorectal cancer. Fam Cancer (2009) 1.01
Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. Eur J Cancer (2010) 1.01
TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin Cancer Res (2007) 1.00